JP2024538129A5 - - Google Patents
Info
- Publication number
- JP2024538129A5 JP2024538129A5 JP2024522503A JP2024522503A JP2024538129A5 JP 2024538129 A5 JP2024538129 A5 JP 2024538129A5 JP 2024522503 A JP2024522503 A JP 2024522503A JP 2024522503 A JP2024522503 A JP 2024522503A JP 2024538129 A5 JP2024538129 A5 JP 2024538129A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- tumor antigen
- specific
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163256427P | 2021-10-15 | 2021-10-15 | |
| US63/256,427 | 2021-10-15 | ||
| US202263327286P | 2022-04-04 | 2022-04-04 | |
| US63/327,286 | 2022-04-04 | ||
| PCT/US2022/078161 WO2023064930A1 (en) | 2021-10-15 | 2022-10-14 | T cell manufacturing compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024538129A JP2024538129A (ja) | 2024-10-18 |
| JP2024538129A5 true JP2024538129A5 (cg-RX-API-DMAC7.html) | 2025-10-17 |
Family
ID=85988935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024522503A Pending JP2024538129A (ja) | 2021-10-15 | 2022-10-14 | T細胞製造組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250195659A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4415728A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024538129A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022362079A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3234993A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312121A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023064930A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7054418B2 (ja) | 2017-11-08 | 2022-04-13 | ビオンテック ユーエス インコーポレイテッド | T細胞を製造する組成物及び方法 |
| TWI867324B (zh) | 2019-05-08 | 2024-12-21 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
| WO2025189025A2 (en) * | 2024-03-07 | 2025-09-12 | Biontech Us Inc. | Methods and compositions for engineering t cells |
| WO2025245488A2 (en) * | 2024-05-24 | 2025-11-27 | Biontech Us Inc. | Compositions and methods for t cell manufacturing and uses thereof |
| US20260003646A1 (en) * | 2024-06-26 | 2026-01-01 | Truist Bank | Ordering of digital communications for display on a gui |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7054418B2 (ja) * | 2017-11-08 | 2022-04-13 | ビオンテック ユーエス インコーポレイテッド | T細胞を製造する組成物及び方法 |
| TW201930340A (zh) * | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| US20220282217A1 (en) * | 2019-03-30 | 2022-09-08 | Biontech Us Inc. | Compositions and methods for preparing t cell compositions and uses thereof |
| TWI867324B (zh) * | 2019-05-08 | 2024-12-21 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
-
2022
- 2022-10-14 IL IL312121A patent/IL312121A/en unknown
- 2022-10-14 AU AU2022362079A patent/AU2022362079A1/en active Pending
- 2022-10-14 EP EP22882062.7A patent/EP4415728A4/en active Pending
- 2022-10-14 CA CA3234993A patent/CA3234993A1/en active Pending
- 2022-10-14 JP JP2024522503A patent/JP2024538129A/ja active Pending
- 2022-10-14 US US18/701,073 patent/US20250195659A1/en active Pending
- 2022-10-14 WO PCT/US2022/078161 patent/WO2023064930A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kinkead et al. | Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer | |
| Liu et al. | Engineering neoantigen vaccines to improve cancer personalized immunotherapy | |
| US20220016164A1 (en) | Pharmaceutical composition for use in the treatment of pancreatic cancer | |
| Gabrilovich et al. | Dendritic cells in antitumor immune responses: I. Defective antigen presentation in tumor-bearing hosts | |
| Palucka et al. | Taming cancer by inducing immunity via dendritic cells | |
| Townsend et al. | Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells | |
| Ahlers et al. | High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection | |
| Rapoport et al. | Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells | |
| Yuan et al. | Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma | |
| JP2024038503A5 (cg-RX-API-DMAC7.html) | ||
| JP2021502414A5 (cg-RX-API-DMAC7.html) | ||
| Aspord et al. | HLA-A* 0201+ plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients | |
| Faure et al. | Long‐lasting cross‐presentation of tumor antigen in human DC | |
| Knutson et al. | IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion | |
| TW202003030A (zh) | 新抗原表位疫苗及免疫刺激組合物及方法 | |
| Palucka et al. | Harnessing dendritic cells to generate cancer vaccines | |
| JP2008526763A (ja) | 予防又は治療目的のmhcクラスi拘束性エピトープに対する免疫応答の誘導、増強及び保持方法 | |
| Llopiz et al. | Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy | |
| Kirkpatrick et al. | Deciphering CD4+ T cell‐mediated responses against cancer | |
| ES2340358T3 (es) | Uso de lineas celulares alogenicas para cargar celulas que presentan antigenos para elicitar respuestas inmunes. | |
| Kogo et al. | Suppression of murine tumour growth through CD 8+ cytotoxic T lymphocytes via activated DEC‐205+ dendritic cells by sequential administration of α‐galactosylceramide in vivo | |
| Goldman et al. | Effective elimination of lung metastases induced by tumor cells treated with hydrostatic pressure and N-acetyl-L-cysteine | |
| Pan et al. | Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention | |
| Cohen et al. | Use of interleukin-7, interleukin-2, and interferon-γ to propagate CD4+ T cells in culture with maintained antigen specificity | |
| Anderson et al. | Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides |